Dr. Kenneth Offit is Chief of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center, a Member of the Program in Cancer Biology and Genetics at the Sloan Kettering Institute, and a Professor of Medicine and Public Health at the Weill College of Medicine of Cornell University. He is a graduate of Princeton University, the Harvard School of Public Health, and the Harvard Medical School. His laboratory team discovered the most commonly recurring BRCA2 mutation associated with inherited breast, ovarian, and prostate cancer, as well as common variants that modify BRCA2 associated risk of cancer. His group initially described PAX5 and ETV6 syndromes susceptibility to inherited lymphoblastic leukemia as well as genomic variants associated with risk for lymphoma, colon, bladder, and prostate cancer. In 2013 he received the American Society of Clinical Oncology-American Cancer Society award for his work in cancer prevention.  He is co-Chair of the Hereditary Cancer Working Group the ClinGen effort of the National Human Genome Research Institute. In 2016, he was elected into the National Academy of Medicine and in 2018 as a Fellow of the American Society of Clinical Oncology.